AECHL-1 targets breast cancer progression via inhibition of metastasis, prevention of EMT and suppression of Cancer Stem Cell characteristics

• DOI: 10.1038/srep38045
• Publication Date: 2016-12-15T11:24:00Z
• Authors: Aparajita Dasgupta; Mithila A. Sawant; Gayatri Kavishwar; Manish Lavhale; Sandhya Sitasawad
• Keywords: Triple-negative breast cancer

Triple negative breast cancer (TNBC) features among the most aggressive manifestations of due to its enhanced metastatic potential and immunity therapeutics which target hormone receptors. Under such scenarios, anti-cancer compounds with an ability influence multiple targets, or entire process, will have advantage over specific signal transduction inhibitors. To counter threat it is essential cellular components central processes cell migration adaptation. Our previous work on a novel triterpenoid, AECHL-1, explored potential, linked elevated ER stress in cells, while anti-angiogenic was credited for manipulate cytoskeleton. Here, we broaden range action by showing that curbs TNBC both vitro MDA-MB-231 line vivo, mouse models metastasis. AECHL-1 does so disrupting cytoskeletal network, also suppressing NF-κB β-Catenin mediated key molecular pathways. These activities contributed suppression TGF-β/TNF-α induced Epithelial Mesenchymal Transition (EMT) stem characteristic. Thus, present as promising therapeutic inhibitor disease.